OPG recombinant protein

OPG

Cat. Num. AAA517356

• Gene Names: TNFRSF11B; OPG; TR1; OCIF; PDB5
• Applications: Cell Assay
• Synonyms: OPG; TNFRSF11B; TR1; OCIF; MGC29565; OPG recombinant protein

• Host: E Coli
• Form/Format: Recombinant protein stored in 1 X PBS, 10% glycerol.

• Applicable Applications for OPG recombinant protein: Cell Assay
• Species: Human
• Endotoxin Level: Less than 0.1ng/ug (IEU/ug) of OPG.
• Preparation and Storage: Store at desiccated below -20 degree C. It is stable at 4 degree C between 2-7 days. For long term storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

SDS-Page

(Purity: Sample Purity Data. For specific information on a given lot, see related technical data sheet.)

Related Product Information for OPG recombinant protein

Recombinant human OPG was expressed in E Coli cells and purified by proprietary chromatographic techniques. The protein accession number is NP_002537.
OPG is an 11b member of tumor necrosis factor receptor superfamily which is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. OPG can act as a soluble factor in the regulation of bone mass and it may be useful in the treatment of osteoporosis associated with increased osteoclast activity (1). osteoprotegerin (OPG) is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. OPG also play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential (2).

Product Categories/Family for OPG recombinant protein

Growth Factors; Cardiovascular Disease; Inflammation

References

1. Simonet, W. S. et.al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.
2. Croucher, P. I. et.al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001.

NCBI and Uniprot Product Information

• NCBI GI #: 148743793
• NCBI GeneID: 4982
• NCBI Accession #: NP_002537
• NCBI GenBank Nucleotide #: NM_002546.3
• UniProt Accession #: O00300; O60236; Q53FX6; Q9UHP4; B2R9A8
• Molecular Weight: 44.7 kDa (389 aa) (On SDS-PAGE under denatured condition, apparent molecular weight of glycosylated rhOPG protein will appear at approximately 55kDa)
• NCBI Official Full Name: tumor necrosis factor receptor superfamily member 11B
• NCBI Official Synonym Full Names: TNF receptor superfamily member 11b
• NCBI Official Symbol: TNFRSF11B
• NCBI Official Synonym Symbols: OPG; TR1; OCIF; PDB5
• NCBI Protein Information: tumor necrosis factor receptor superfamily member 11B
• UniProt Protein Name: Tumor necrosis factor receptor superfamily member 11B
• UniProt Gene Name: TNFRSF11B
• UniProt Synonym Gene Names: OCIF; OPG
• UniProt Entry Name: TR11B_HUMAN

NCBI Description

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

Uniprot Description

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.

Protein type: Secreted; Inhibitor; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 8q24

Cellular Component: extracellular space; proteinaceous extracellular matrix; extracellular region

Molecular Function: cytokine activity; receptor activity

Biological Process: response to drug; response to magnesium ion; extracellular matrix organization and biogenesis; negative regulation of odontogenesis of dentine-containing teeth; response to estrogen stimulus; apoptosis; response to arsenic; signal transduction; negative regulation of bone resorption; skeletal development; response to nutrient

Disease: Paget Disease, Juvenile